The effect of montelukast, a leukotriene receptor antagonist, on the acetic acid-induced model of colitis in rats: Involvement of NO-cGMP-K
KATP channels
cGMP
cyclic guanosine monophosphate
inflammatory bowel disease
montelucast
nitric oxide
rats
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
08
2022
accepted:
08
09
2022
entrez:
13
10
2022
pubmed:
14
10
2022
medline:
14
10
2022
Statut:
epublish
Résumé
Inflammatory bowel disease is a chronic autoimmune disorder that may involve entire gastrointestinal tract. The leukotrienes have a role as mediators in the pathophysiology of colitis. Here, we investigated the effect of a leukotriene receptor antagonist, montelukast, and also the role of the NO-cGMP-K
Identifiants
pubmed: 36225573
doi: 10.3389/fphar.2022.1011141
pii: 1011141
pmc: PMC9549743
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1011141Informations de copyright
Copyright © 2022 Ghorbanzadeh, Behmanesh, Mahmoudinejad, Zamaniyan, Ekhtiar and Paridar.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biochem Biophys Rep. 2020 Jul 24;23:100790
pubmed: 32760814
Can J Physiol Pharmacol. 2006 May;84(5):531-7
pubmed: 16902598
Eur J Pharmacol. 2016 May 15;779:38-45
pubmed: 26948314
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Int J Neurosci. 2021 Oct;131(10):1004-1011
pubmed: 32408781
Clin Exp Pharmacol Physiol. 2001 Jan-Feb;28(1-2):9-12
pubmed: 11153546
J Gastroenterol Hepatol. 2011 Jul;26(7):1174-81
pubmed: 21401719
Pediatr Pulmonol. 2000 Jan;29(1):46-61
pubmed: 10613787
J Exp Med. 2001 Nov 5;194(9):1207-18
pubmed: 11696587
Digestion. 1978;17(2):135-50
pubmed: 627326
J Gastroenterol. 1995 Feb;30(1):34-40
pubmed: 7719412
Curr Rev Pain. 2000;4(6):459-66
pubmed: 11060592
Clin Colon Rectal Surg. 2018 May;31(3):168-178
pubmed: 29720903
Gastroenterology. 2000 Oct;119(4):1007-18
pubmed: 11040187
Pharmacol Biochem Behav. 2019 May;180:92-100
pubmed: 30857920
Digestion. 1986;35(4):199-204
pubmed: 3817329
Am J Physiol. 1994 Sep;267(3 Pt 2):H931-7
pubmed: 7522408
Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G865-74
pubmed: 15217783
Prostaglandins. 1986 Apr;31(4):795-809
pubmed: 3014611
Clin Exp Immunol. 2004 Nov;138(2):323-9
pubmed: 15498044
Gastroenterology. 2000 Aug;119(2):512-20
pubmed: 10930387
Int Immunopharmacol. 2003 Nov;3(12):1581-8
pubmed: 14555283
Pharmacol Rep. 2020 Feb;72(1):135-146
pubmed: 32016839
Blood. 1999 Feb 15;93(4):1399-405
pubmed: 9949184
Inflamm Bowel Dis. 2007 May;13(5):537-46
pubmed: 17230539
Fundam Clin Pharmacol. 2012 Apr;26(2):190-3
pubmed: 21777273
J Physiol Pharmacol. 2007 Sep;58(3):455-67
pubmed: 17928642
Gut. 1995 Aug;37(2):247-55
pubmed: 7557576
Eur J Pharmacol. 1982 Mar 26;78(4):463-6
pubmed: 6896184
Inflamm Bowel Dis. 2007 Mar;13(3):308-16
pubmed: 17206708
J Pharmacol Exp Ther. 2009 Sep;330(3):764-70
pubmed: 19491326
Toxicol Lett. 2003 Nov 1;145(1):79-87
pubmed: 12962976
PLoS One. 2013 Nov 11;8(11):e79180
pubmed: 24244444
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
Immunology. 2004 Dec;113(4):427-37
pubmed: 15554920
Inflamm Bowel Dis. 2006 Jan;12 Suppl 1:S3-9
pubmed: 16378007
Am J Physiol Gastrointest Liver Physiol. 2016 Apr 1;310(7):G460-76
pubmed: 26744474
Scand J Gastroenterol. 2015 Jan;50(1):90-112
pubmed: 25523560
Scand J Gastroenterol. 1999 Oct;34(10):962-6
pubmed: 10563664
Endocr Metab Immune Disord Drug Targets. 2018;18(4):362-370
pubmed: 29237389
Behav Pharmacol. 2021 Feb 1;32(1):32-42
pubmed: 33290345
Mol Cells. 2001 Aug 31;12(1):97-102
pubmed: 11561736
Acta Med Iran. 2013;51(10):675-80
pubmed: 24338138
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646